ArticleThyroid : official journal of the American Thyroid Association2014
A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
Article in Thyroid : official journal of the American Thyroid Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Innovative immunotherapeutic strategies for thyroid cancer: challenges and opportunities.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment-Implications for Therapy.Cancers · 2026Review
- Immune evolution and therapeutic vulnerabilities in thyroid cancer: from inflammation to immune escape.Frontiers in immunology · 2026Review
- Epigenetic Regulation of Immune Responses in Endocrine-Related Cancers and Its Role in Immunotherapy.Cancers · 2025Review
- NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.Clinical and translational medicine · 2024Review
- Bridging the divide: unveiling mutual immunological pathways of cancer and pregnancy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Review
- Advances in targeted therapy and biomarker research in thyroid cancer.Frontiers in endocrinology · 2024Review
- Cell Component and Function of Tumor Microenvironment in Thyroid Cancer.International journal of molecular sciences · 2022Review
- Current understanding of nonsurgical interventions for refractory differentiated thyroid cancer: a systematic review.Future science OA · 2021Review
- MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.International journal of molecular sciences · 2021Review
- From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer.Theranostics · 2021Review
- Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.Acta pharmaceutica Sinica. B · 2020Review
- Immune Landscape of Thyroid Cancers: New Insights.Frontiers in endocrinology · 2020Review
- Immune Microenvironment of Thyroid Cancer.Journal of Cancer · 2020Review
- DNA Methyltransferase Inhibitors: Catalysts For Antitumour Immune Responses.OncoTargets and therapy · 2019Review
- Co-delivery of human cancer-testis antigens with adjuvant in protein nanoparticles induces higher cell-mediated immune responses.Biomaterials · 2018Article
- NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.Frontiers in immunology · 2018Review
- Expression of cancer/testis antigens MAGE-A, MAGE-C1, GAGE and CTAG1B in benign and malignant thyroid diseases.Oncology letters · 2017Article
- T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Laboratory investigation; a journal of technical methods and pathology · 2017Review
- Improving cancer immunotherapy with DNA methyltransferase inhibitors.Cancer immunology, immunotherapy : CII · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNY-ESO-1 is one of the most immunogenic members of the cancer/testis antigen family and its levels can be increased after exposure to demethylating and deacetylating agents. This cytoplasmic antigen can serve as a potent target for cancer immunotherapy and yet has not been well studied in differentiated thyroid cancer cells.
methodsWe studied the baseline expression of NY-ESO-1 messenger RNA and protein before and after exposure to 5-aza-2'-deoxycytidine (DAC) (72 hours) in a panel of thyroid cancer cell lines using quantitative polymerase chain reaction and Western blot. HLA-A2+, NY-ESO-1+ thyroid cell lines were then co-cultured with peripheral blood lymphocytes transduced with NY-ESO-1 specific T-cell receptor (TCR) and assayed for interferon-gamma and Granzyme-B release in the medium. SCID mice injected orthotopically with BCPAP cells were treated with DAC to evaluate for NY-ESO-1 gene expression in vivo.
resultsNone of the thyroid cancer cell lines showed baseline expression of NY-ESO-1. Three cell lines, BCPAP, TPC-1, and 8505c, showed an increase in NY-ESO-1 gene expression with DAC treatment and were found to be HLA-A2 positive. DAC-treated target BCPAP and TPC-1 tumor cells with up-regulated NY-ESO-1 levels were able to mount an appropriate interferon-gamma and Granzyme-B response upon co-culture with the NY-ESO-1-TCR-transduced peripheral blood lymphocytes. In vivo DAC treatment was able to increase NY-ESO-1 expression in an orthotopic mouse model with BCPAP cells.
conclusionOur data suggest that many differentiated thyroid cancer cells can be pressed to express immune antigens, which can then be utilized in TCR-based immunotherapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.